Off-Target


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
20 01 2021
Historique:
received: 22 10 2020
accepted: 20 11 2020
pubmed: 25 11 2020
medline: 30 1 2021
entrez: 24 11 2020
Statut: epublish

Résumé

Remdesivir (RDV, GS-5734), the first FDA-approved antiviral for the treatment of COVID-19, is a single diastereomer monophosphoramidate prodrug of an adenosine analogue. It is intracellularly metabolized into the active triphosphate form, which in turn acts as a potent and selective inhibitor of multiple viral RNA polymerases. RDV has broad-spectrum activity against members of the coronavirus family, such as SARS-CoV-2, SARS-CoV, and MERS-CoV, as well as filoviruses and paramyxoviruses. To assess the potential for off-target toxicity, RDV was evaluated in a set of cellular and biochemical assays. Cytotoxicity was evaluated in a set of relevant human cell lines and primary cells. In addition, RDV was evaluated for mitochondrial toxicity under aerobic and anaerobic metabolic conditions, and for the effects on mitochondrial DNA content, mitochondrial protein synthesis, cellular respiration, and induction of reactive oxygen species. Last, the active 5'-triphosphate metabolite of RDV, GS-443902, was evaluated for potential interaction with human DNA and RNA polymerases. Among all of the human cells tested under 5 to 14 days of continuous exposure, the 50% cytotoxic concentration (CC

Identifiants

pubmed: 33229429
pii: AAC.02237-20
doi: 10.1128/AAC.02237-20
pmc: PMC7849018
pii:
doi:

Substances chimiques

Antiviral Agents 0
remdesivir 3QKI37EEHE
Adenosine Monophosphate 415SHH325A
Alanine OF5P57N2ZX

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Xu et al.

Références

JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
Bioorg Med Chem Lett. 2015 Jun 15;25(12):2484-7
pubmed: 25978965
J Biol Chem. 2001 Nov 2;276(44):40847-57
pubmed: 11526116
PLoS Pathog. 2012;8(11):e1003030
pubmed: 23166498
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Toxicol Sci. 2003 Oct;75(2):355-67
pubmed: 12883091
Annu Rev Pharmacol Toxicol. 2011;51:1-24
pubmed: 20809796
J Bioenerg Biomembr. 2012 Aug;44(4):421-37
pubmed: 22689143
Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618758524
pubmed: 29534607
Antimicrob Agents Chemother. 2002 Mar;46(3):716-23
pubmed: 11850253
Toxicol Sci. 2007 Jun;97(2):539-47
pubmed: 17361016
Nat Biotechnol. 2014 Apr;32(4):373-80
pubmed: 24658645
PLoS Pathog. 2018 Feb 9;14(2):e1006889
pubmed: 29425244
Sci Transl Med. 2019 May 29;11(494):
pubmed: 31142680
Biochemistry. 2011 Jun 7;50(22):5016-32
pubmed: 21548588
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Liver Int. 2018 Feb;38 Suppl 1:7-13
pubmed: 29427484
Antimicrob Agents Chemother. 2014;58(4):1930-42
pubmed: 24419349
Free Radic Biol Med. 2011 Nov 1;51(9):1621-35
pubmed: 21872656
Anal Biochem. 2010 Sep 1;404(1):75-81
pubmed: 20465991
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
Antimicrob Agents Chemother. 2015 Nov 23;60(2):806-17
pubmed: 26596942
J Infect Dis. 2020 Nov 9;222(11):1894-1901
pubmed: 32479636
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Clin Transl Sci. 2020 Sep;13(5):896-906
pubmed: 32589775
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440

Auteurs

Yili Xu (Y)

Gilead Sciences, Inc., Foster City, California, USA.

Ona Barauskas (O)

Gilead Sciences, Inc., Foster City, California, USA.

Cynthia Kim (C)

Gilead Sciences, Inc., Foster City, California, USA.

Darius Babusis (D)

Gilead Sciences, Inc., Foster City, California, USA.

Eisuke Murakami (E)

Gilead Sciences, Inc., Foster City, California, USA.

Dmytro Kornyeyev (D)

Gilead Sciences, Inc., Foster City, California, USA.

Gary Lee (G)

Gilead Sciences, Inc., Foster City, California, USA.

George Stepan (G)

Gilead Sciences, Inc., Foster City, California, USA.

Michel Perron (M)

Gilead Sciences, Inc., Foster City, California, USA.

Roy Bannister (R)

Gilead Sciences, Inc., Foster City, California, USA.

Brian E Schultz (BE)

Gilead Sciences, Inc., Foster City, California, USA.

Roman Sakowicz (R)

Gilead Sciences, Inc., Foster City, California, USA.

Danielle Porter (D)

Gilead Sciences, Inc., Foster City, California, USA.

Tomas Cihlar (T)

Gilead Sciences, Inc., Foster City, California, USA.

Joy Y Feng (JY)

Gilead Sciences, Inc., Foster City, California, USA joy.feng@gilead.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH